EUVIMEDEUVIMED entdecken
Crossref

Alogliptin repositioning confers protection against diclofenac-induced liver injury by inhibiting TLR4/NF-κB, ROS/TXNIP, and NLRP3 inflammasome-mediated pyroptosis in rats

Nermein F El Sayed, Mohamed H Noureldin, Ibrahim El Sayed, Yousra Y El Banna, Mai El-Sayed Ghoneim iD

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04666-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Nermein F El Sayed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Diclofenac, Uracil, Piperidines. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-induced liver injury (DILI) is a significant contributor to post-marketing concerns and drug withdrawals. Diclofenac (Diclo), a nonsteroidal anti-inflammatory drug, has the potential to cause liver injury. Given the current limitations, there is a great demand for finding effective and safe preventive therapies for liver injury. Alogliptin (Alo), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has multifaceted properties; however, its protective effect against Diclo-triggered liver damage remains unveiled. This study aimed to explore the hepatoprotective effect of Alo versus Diclo-evoked liver insult and decipher the underlying molecular mechanisms. Experimental rats were arbitrarily allocated into four groups: Control, Diclo, Alo 20, and Alo 40. Liver injury was evaluated microscopically, and molecular perturbations were estimated by measuring inflammatory, inflammasome, apoptotic, and oxidative stress markers. Our results showed that Alo evidently abrogated Diclo-instigated liver injury, as verified by reduced levels of ALT, AST, and LDH, along with the restoration of liver histoarchitecture. Furthermore, Alo pretreatment remarkably inhibited the perturbations in redox balance induced by Diclo, together with a reduction in inflammatory mediators and apoptotic markers. Mechanistically, Alo pretreatment effectively abated the inflammasome moieties and gasdermin D-N terminal via averting TLR4/TRAF6/NF-κB and ROS/TXNIP signaling pathways, while boosting Nrf2, ultimately curbing Diclo-induced pyroptotic cell death. This study validated the interplay among the TLR4/TRAF6/NF-κB/NLRP3/ASC/cleaved caspase-1, Nrf2/TXNIP, and ROS/TXNIP signaling trajectories in mediating Diclo-induced pyroptosis. Furthermore, it revealed that a dose-dependent hepatoprotective effect of Alo signifies its antioxidant, anti-inflammatory, anti-apoptotic, and anti-pyroptotic actions that could offer a promising strategy for alleviating Diclo-induced hepatotoxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryDiclofenacUracilPiperidinesDipeptidyl-Peptidase IV InhibitorsAnimalsNLR Family, Pyrin Domain-Containing 3 ProteinToll-Like Receptor 4MaleNF-kappa BInflammasomesReactive Oxygen SpeciesRatsPyroptosisLiverSignal TransductionAnti-Inflammatory Agents, Non-SteroidalRats, Sprague-DawleyOxidative Stress

Stichwörter der Autor:innen

AlogliptinApoptosisDiclofenacInflammationLiver injuryNLRP3 inflammasomePyroptosis

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinToll-Like Receptor 4NF-kappa BalogliptinInflammasomesNlrp3 protein, ratDiclofenacTlr4 protein, ratReactive Oxygen SpeciesUracil

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
  • Department of Biochemistry, Clinical and Biological Sciences Division, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, P.O. Box 1029, Alexandria, Egypt.
  • Department of Pharmacy, Collage of Pharmacy, Nursing and Medical Sciences, Riyadh Elm University, Riyadh, Saudi Arabia.
  • Department of Pharmacology and Toxicology, Clinical and Biological Sciences Division, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, P.O. Box 1029, Alexandria, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Sadat City (USC), Sadat City, 32897, Egypt. mai.ghoneim@fop.usc.edu.eg.

ORCID-Profile: Mai El-Sayed Ghoneim

Zitieren

APA

El Sayed, N. F., Noureldin, M. H., El Sayed, I., El Banna, Y. Y., & Ghoneim, M. E. (2025). Alogliptin repositioning confers protection against diclofenac-induced liver injury by inhibiting TLR4/NF-κB, ROS/TXNIP, and NLRP3 inflammasome-mediated pyroptosis in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04666-y

Vancouver

El Sayed NF, Noureldin MH, El Sayed I, El Banna YY, Ghoneim ME. Alogliptin repositioning confers protection against diclofenac-induced liver injury by inhibiting TLR4/NF-κB, ROS/TXNIP, and NLRP3 inflammasome-mediated pyroptosis in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04666-y

BibTeX
@article{ElSayed2025,
  author = {El Sayed, Nermein F and Noureldin, Mohamed H and El Sayed, Ibrahim and El Banna, Yousra Y and Ghoneim, Mai El-Sayed},
  title = {Alogliptin repositioning confers protection against diclofenac-induced liver injury by inhibiting TLR4/NF-κB, ROS/TXNIP, and NLRP3 inflammasome-mediated pyroptosis in rats},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04666-y}
}
Kostenlos starten →